Dry AMD separates itself from wet AMD by lacking any vascular involvement in its pathological course. The loss of RPE cells in dry AMD progresses to its most severe manifestation – geographic atrophy (GA), where well-defined, geographic areas of atrophy develop in the macula, stealing central vision. Approval of complement inhibitors Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) for slowing GA progression offered much needed hope in developing better treatments for dry AMD/GA. Our study directors at PharmaLegacy have a long history of investigating complement and dry AMD. As a multi-factorial disease, dry AMD/GA efficacy studies often require careful design, to suite different treatment strategies and therapeutic targets.